Clinical trials: RSV
RSV Infection
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice.
- Trial name
- NCT06172660
- Testing
- Nirsevimab
- Where
- United States
- Volunteers
- 3,750 people
- Sponsor
- Yale University
RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the…
- Conditions
- RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy, Healthy
- Trial name
- CosTaR (NCT07097012)
- Testing
- Tdap Vaccine Administration, RSV Vaccine
- Where
- 4 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Immunization Research Network
Respiratory Syncytial Virus (RSV)
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults
This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.
- Trial name
- NCT07885956
- Testing
- RSVpreF (Regimen A), RSVpreF (Regimen B)
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection, Influenza A
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
- Trial name
- CorDx 4in1 (NCT07875270)
- Testing
- Flu A/B/COVID-19 + RSV Multiplex Rapid Test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorDx, Inc.
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Immunization
RSV Immunisation Status in Queensland (Australia)
The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.
- Trial name
- NCT07615192
- Testing
- Nirsevimab Respiratory Syncytial Virus monoclonal antibody
- Where
- Australia
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- Sanofi
Respiratory Syncytial Virus (RSV)
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised…
- Trial name
- NCT07768345
- Testing
- RSVpreF Vaccine
- Where
- 17 sites in United States
- Volunteers
- 440 people
- Sponsor
- Pfizer
RSV Immunization
Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China
The goal of this clinical trial is to evaluate whether an AI-assisted primary care intervention for parents can increase RSV monoclonal antibody (mAb) uptake among infants, and to assess the cost-effectiveness and potential for…
- Trial name
- NCT07856290
- Testing
- RSV AI-assisted primary care intervention
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Fudan University
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine…
- Trial name
- NCT07860216
- Testing
- Recombinant respiratory syncytial virus vaccine (CHO cell), Sodium Chloride Injection 0.9%
- Where
- 7 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Beijing BeneWill Technology Development Co., Ltd
RSV Immunization
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12…
- Trial name
- CORAL (NCT06397768)
- Testing
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine
- Where
- 72 sites in United States, Mexico and 1 more
- Volunteers
- 2,226 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV-2 Infection, RSV
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to…
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Trial name
- COPE-VA (NCT06160128)
- Where
- United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
RSV Immunisation
RSV Immunogenicity Study in the Elderly (RISE)
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly.
- Trial name
- RISE (NCT07203365)
- Testing
- This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65
- Where
- 2 sites in Sweden
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Karin Karin Loré
Respiratory Syncytial Virus (RSV)
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.
- Trial name
- NCT07543380
- Testing
- RSVpreF
- Where
- 5 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
- Trial name
- NCT07653100
- Testing
- RSVpreF
- Where
- 13 sites in India
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV)
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
- Trial name
- NCT07839871
- Testing
- RSVpreF
- Where
- 2 sites in United States, Japan
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy.
- Trial name
- NCT07824167
- Testing
- Clesrovimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Respiratory Syncytial Virus (RSV)
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
- Trial name
- NCT07694557
- Testing
- YKYY025 group
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Influenza Viruses, Respiratory Syncytial Virus (RSV)
ELderly REspiratory VIral Cohort
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and…
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV)
- Trial name
- ELREVI (NCT07813481)
- Testing
- Respiratory viral infection
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus (RSV)
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children who are at high-risk of RSV disease.
- Trial name
- Synagis (NCT06851806)
- Testing
- Palivizumab 15 mg/kg
- Where
- 9 sites in India
- Volunteers
- 21 people
- Sponsor
- AstraZeneca